Americans Are Living Longer Than Ever. Public Health Deserves the Credit.

Read Time: 5 min

Amid all the commercial noise about longevity supplements, full-body scans, and personalized blood panels, one of the most important recent stories about how long Americans actually live passed through the news cycle with surprisingly little fanfare. The CDC’s annual report on life expectancy — the closest thing public health has to a vital sign for the entire nation — showed that life expectancy for the U.S. population in 2024 rose 0.6 years to 79 years, the highest level ever recorded. That is a genuinely significant finding, and it deserves more sustained public attention than it received.

Part of the reason it did not receive that attention is structural. In public health, we measure vital statistics — births, deaths, and causes of death across entire communities — rather than the vital signs of individual patients. This population-level work is methodologically sophisticated and consequential, but it generates neither the visceral urgency of a personal diagnosis nor the aspirational appeal of a biohacking protocol. It is, in that sense, the opposite of good marketing material. The people whose work drives gains in population life expectancy rarely appear in Super Bowl ads or bestseller lists. They work in health departments, research institutions, and international agencies, and their contributions accumulate over decades in ways that resist simple attribution.

What Actually Drives Longevity at the Population Level

Understanding why Americans live longer than they did a century ago requires looking in places the longevity industry rarely directs its attention. The largest gains in life expectancy over the past hundred years came primarily from improvements in water, sanitation, and hygiene — interventions that are decidedly unglamorous and that required collective investment rather than individual purchase. Medical interventions, including vaccines and antibiotics, followed and contributed substantially, but they built on a foundation of environmental and infrastructural change that preceded them.

Even today, the best available estimates suggest that medical care accounts for only 5% to 15% of improvements in life expectancy, with the remainder driven by social, behavioral, and environmental factors. That is a finding with profound implications for how we allocate attention and resources in the health sector, and it sits in direct tension with the assumptions embedded in most longevity industry marketing, which positions individual medical consumption — the right scan, the right supplement, the right blood panel — as the primary lever available to people who want to live longer.

The 2024 CDC report also documented meaningful progress on specific causes of death. The top three — heart disease, cancer, and unintentional injuries — remained unchanged from prior years, but there was a substantial decline in overdose deaths, and Covid-19 dropped out of the ten leading causes of death entirely. These shifts reflect years of sustained public health effort: harm reduction programs, expanded access to medication-assisted treatment for opioid use disorder, improved clinical management of Covid-19, and vaccination campaigns that reduced severe disease and death. None of those achievements arrived through a subscription service or a concierge retainer.

The Social Determinants That the Industry Cannot Sell You

There is a version of the longevity conversation that the commercial industry is structurally unable to have, because its conclusions do not translate into purchasable products. The evidence on what actually predicts how long individuals live points consistently toward factors that operate at the level of social structure rather than individual consumption. Educational attainment is among the strongest predictors of life expectancy in high-income countries. Income matters enormously, both directly — through its effects on nutrition, housing, and access to care — and indirectly, through its relationship with stress, neighborhood conditions, and exposure to environmental hazards. Living in an area with lower air pollution and fewer traffic accidents extends lives in ways that no supplement can replicate.

These are not arguments against clinical medicine, which remains essential and genuinely life-saving for people managing chronic diseases. Too many Americans still die from inadequate care for diabetes, high blood pressure, asthma, HIV, and a long list of other conditions where effective treatment exists but access remains unequal. Cancer screening — for breast, cervical, and colon cancer specifically — rests on strong evidence that early detection improves both the length and quality of life, and those programs deserve sustained investment and expanded reach.

The point is proportionality: a clear-eyed accounting of where the evidence is strongest and where the returns on investment, both individual and collective, are largest. By that accounting, clean water, decent wages, quality education, effective vaccination programs, and equitable access to primary care have done more to extend human life than anything the longevity industry currently sells. That is a conclusion worth sitting with, especially in a moment when public investment in the institutions that deliver those goods is under significant pressure while the market for expensive personal health interventions keeps expanding.